Pharmaceutical pipeline and data

As pharmaceutical companies find it difficult to raise prices in the market place, the profitability--and hence continued development--of new drugs will depend increasingly on reducing the cost of launching new drugs. A significant source of that cost is the Food and Drug Administration's safety and efficacy review. Reducing the time spent in review, and increasing the chance of successfully completing it, will not only reduce the costs of producing new drugs, but ultimately lead to lower market prices for consumers.

New drugs in development

http://www.chartsbank.com/PipelineList.aspx